Sarcoma L-1 in mice as a model for the study of experimental angiogenesis

Central-European Journal of Immunology

Volumn 32, Issue 2, 2007, Pages 77-83

  Skopińska Rózewska, Ewa ^a   Skurzak, Henryk ^b   Wasiutyński, Aleksander ^a   Jung, Leszek ^c   Siwicki, Andrzej K ^d   Bałan, Barbara J ^a   Sommer, Ewa ^a   Mazurkiewicz, Michał ^a   Skorupski, Marcin ^c   Pratnicki, Antoni ^a   Sokolnicka, Irena ^e   Skopiński, Piotr ^f  

^a MEDICAL UNIVERSITY OF WARSAW   (Poland)

^b INSTITUTE OF ONCOLOGY   (Poland)

^c INSTITUTE OF RHEUMATOLOGY   (Poland)

^d UNIVERSITY OF WARMIA AND MAZURY IN OLSZTYN   (Poland)

^e CHILDREN'S MEMORIAL HEALTH INSTITUTE   (Poland)

^f MEDICAL UNIVERSITY OF WARSAW   (Poland)

Author keywords

Angiogenesis; L 1 sarcoma; Low molecular weight heparins; Mice; Tumor growth

Indexed keywords

ENOXAPARIN; FLAXIPARINE; NADROPARIN; UNCLASSIFIED DRUG;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BAGG ALBINO MOUSE; CANCER TRANSPLANTATION; CELL PROLIFERATION; CELL SUSPENSION; CONTROLLED STUDY; EXPERIMENTAL STUDY; HEMOGLOBIN BLOOD LEVEL; IN VIVO STUDY; MOUSE; NONHUMAN; SARCOMA; SARCOMA CELL; TUMOR GROWTH; TUMOR VASCULARIZATION; TUMOR VOLUME;

EID: 34249702844     PISSN: 14263912     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Auerbach R, Lewis R, Shinners B, et al. (2003): Angiogenesis assays: a critical overview. Clin Chem 49: 32-40.
2. Janik P (1976): Lung colony assay in normal, irradiated and tumor bearing mice. Neoplasma 23: 495-497.
3. Wasiutyński A, Skopińska-Rózewska E, Jung L, et al. (2006): Comparison of the effects of enoxaparin and nadroparin on tumor angiogenesis in mice. Centr Eur J Immunol 31: 70-74.
4. Skopińska-Rózewska E, Krotkiewski M, Sommer E, et al. (1999): Inhibitory effect of shark liver oil on cutaneous angiogenesis induced in Balb/c mice by syngeneic sarcoma L-1, human urinary bladder and human kidney tumor cells. Oncol Rep 6: 1341-1344.
5. Skopińska-Rózewska E, Chorostowska-Wynimko J, Krotkiewski M, et al. (2003): Inhibitory effect of Greenland shark liver oil combined with squalen and arctic birch ashes on angiogenesis and L-1 sarcoma growth in Balb/c mice. Pol J Vet Sci 6 (3 suppl): 54-56.
6. Skopińska-Rózewska E, Białas-Chromiec B, Sommer E, et al. (1999): Screening of angiogenesis inhibitors in murine syngeneic sarcoma L-1 model. Int J Mol Med 4 (suppl 1): S40.
7. Sidky YA, Auerbach R (1975): Lymphocyte-induced angiogenesis: a quantitative and sensitive assay of the graft-vs.-host reaction. J Exp Med 141: 1084-1100.
8. Skopińska-Rózewska E, Sommer E, Demkow U, et al. (1997): Screening of angiogenesis inhibitors by modified TIA test in lung cancer. Ann Acad Med Bialost 42 (suppl 1): 287-296.
9. Rogala E, Sommer E, Radomska-Leśniewska D, et al. (2004): Immunomodulatory effects of Panax ginseng preparations on the mouse. Herba Polonica 50: 40-46.
10. Folkman J, Taylor S, Spillberg C. The role of heparin in angiogenesis. In: Development of the vascular system. Pitman Books. London. (Ciba Foundation Symposium 100). 1983, 132-149.
11. Norrby K (1993): Heparin and angiogenesis: a low-molecular-weight fraction inhibits and a high-molecular-weight fraction stimulates angiogenesis systemically. Haemostasis 23 (Suppl 1): 141-149.
12. Norrby K, Ostergaard P (1996): Basic-fibroblast-growth-factor-mediated de novo angiogenesis is more effectively suppressed by low-molecular-weight than by high-molecular-weight heparin. Int J Microcirc Clin Exp 16: 8-15.
13. Norrby K (2000): 2.5 kDa and 5.0 kDa heparin fragments specifically inhibit microvessel sprouting and network formation in VEGF165-mediated mammalian angiogenesis. Int J Exp Pathol 81: 191-198.
14. Castelli R, Porro F, Tarsia P (2004): The heparins and cancer: review of clinical trials and biological properties. Vasc Med 9: 205-213.
15. Jung L, Siwicki AK, Skopińska-Rózewska E, et al. (2005): Enoxaparine increases and fraxiparine decreases angiogenic activity of murine serum independently of the strain of mice. Pol J Environm Studies 14 (Suppl II): 564-568.
16. Fareed J, Leong WL, Hoppensteadt DA, et al. (2004): Generic low-molecular-weight heparins: some practical considerations. Semin Thromb Hemost 30: 703-713.
17. Klerk CP, Smorenburg SM, Otten HM, et al. (2005): The effect of low molecular weight heparin on survival in patients with advanced malignancy. J Clin Oncol 23: 2130-2135.